Global /China /Healthcare /Drug Manufacturers - General /2552

Hua Medicine (Shanghai) Ltd.

2552

• SHEK: 2552 • Delayed

3.35HKD -0.9%

0.4275 USD

As of 16 June 2026, Hua Medicine (Shanghai) Ltd. has a market cap of $429.84M USD, ranking #16190 globally and #5080 in China. It ranks #1456 in the Healthcare sector, and #530 in the Drug Manufacturers - General industry.

Global Rank

16190

Country Rank

5080

Sector Rank

1456

Industry Rank

530

Key Stats

Market Cap

$429.84MUSD

3.37B HKD

Enterprise Value

$317.56MUSD

2.49B HKD

Revenue (TTM)

$70.0MUSD

548.54M HKD

EBITDA (TTM)

-$18.72MUSD

-146.66M HKD

Net Income (TTM)

$157.11MUSD

1.23B HKD

EBITDA Margin

-27%

Profit Margin

224%

PE Ratio

2.8

PS Ratio

6.1

PB Ratio

3.0

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Li Chen open_in_new

Employees

328

Founded

2011

Website

huamedicine.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.9%	-5.7%	-2.6%	7.1%	-6.2%	8.1%	50%	9.2%	-32%

News

Markets

Exchange	Ticker	Price	Quotes
Hong Kong Stock Exchange (SHEK / HKEX) MIC: XHKG PRIMARY	2552 华领医药 ISIN: KYG4644K1022 Shares Out.: Shares Outstanding: 996.525M¹ Shares Float: 601.485M² TV: TradingView: HKEX: 2552 SA: Stock Analysis: HKG: 2552 YF: Yahoo Finance: 2552.HK GF: Google Finance: HKG: 2552 BA: Barron's: 2552 MS: Morningstar: XHKG: 02552	3.35 HKD	TV: TradingView: HKEX: 2552 SA: Stock Analysis: HKG: 2552 YF: Yahoo Finance: 2552.HK GF: Google Finance: HKG: 2552 BA: Barron's: 2552 MS: Morningstar: XHKG: 02552
OTC Markets (OTCMKTS / OTC) MIC: OTCM	HUMDF 华领医药 ISIN: KYG4644K1022 Shares Out.: Shares Outstanding: 983.664M¹ Shares Float: 675.139M² TV: TradingView: OTC: HUMDF SA: Stock Analysis: OTC: HUMDF YF: Yahoo Finance: HUMDF GF: Google Finance: OTCMKTS: HUMDF BA: Barron's: HUMDF MS: Morningstar: PINX: HUMDF	0.4107 USD	TV: TradingView: OTC: HUMDF SA: Stock Analysis: OTC: HUMDF YF: Yahoo Finance: HUMDF GF: Google Finance: OTCMKTS: HUMDF BA: Barron's: HUMDF MS: Morningstar: PINX: HUMDF

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Hua Medicine (Shanghai) Ltd.

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is based in Shanghai, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.89B 364.89B CNY 12K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.67B 336.36B CNY 11K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 7K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 4K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.52B 111.89B CNY 4K%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 4K%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 177K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 127K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 84K%	97.4	United States
Roche Holding AG SIX: RO	$320.51B 256.25B CHF 74K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.14B 215.59B GBP 67K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 64K%	15.1	United States

chevron_leftBack